Abstract:Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. Neuroblastoma is a highly heterogeneous tumor accounting for 15% of all pediatric cancer deaths. Neuroblastoma is an embryonal malignancy pediatric tumor that from sympathetic neural crest cells and showing heterogeneous biological, morphological, genetic and clinical behaviour, ranging from fatal progression to differentiation into benign ganglioneuroma. The correct stratification of neuroblastoma patients within risk groups (low, intermediate, high and ultra-high) is critical for the adequate treatment of the patients. Neuroblastoma remains a significant challenge as high-risk. Patients are treated with intensive multimodal therapies but cure rates remain suboptimal. Even targeted chemotherapies against solid cancers show a moderate success increasing the need to novel targeting strategies. To address this problem we review the effect of protein on neuroblastoma. PEST-containing nuclear protein (PCNP), a novel nuclear protein, is involved in cell proliferation and tumorigenesis. However, the precise mechanism of action of PCNP in the process of tumor growth has not yet been fully elucidated. PCNP successfully mediates the proliferation, migration, and invasion of human neuroblastoma cells through mitogen-activated protein kinase and PI3K/AKT/mTOR signaling pathways, implying that PCNP is a therapeutic target for patients with neuroblastoma. *Corresponding author: Dong-Dong Wu, School of Basic Medical Sciences, Henan University College of Medicine, Kaifeng, Henan, China, Tel: +86371 23880525; E-mail: ddwubiomed2010@163.com Xin-Ying Ji, School of Basic Medical Sciences, Henan University College of Medicine, Kaifeng, Henan, China, Tel: +8637123880585; E-mail: 10190096@vip.henu.edu.cn Received January 23, 2019; Accepted March 22, 2019; Published April 05, 2019 Citation: Saddozai UAK, Khattak S, Abbas A, Khan FA, Wu DD, et al. (2019) PCNP is a Novel Regulator of Neuroblastomas Cancer. J Clin Neurol Neurosurg 2: 106. Copyright: © 2019 Saddozai UAK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CD146 is a potential immunotarget for neuroblastoma

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis

Humoral Immune Response Induced by an Engineered Cell-Based Neuroblastoma Vaccine with or Without CD25 Blockade.

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model

Immune characterization of pre-clinical murine models of neuroblastoma

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Aberrantly expressed Bruton’s tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells

Novel Multi-Targeted ErbB Family Inhibitor Afatinib Blocks EGF-induced Signaling and Induces Apoptosis in Neuroblastoma.

Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastoma

Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma

High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models

PCNP is a Novel Regulator of Neuroblastomas Cancer

Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma

High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy